TherapeuticsMD (TXMD) Q2 2025 earnings summary

Executive summary

• Transitioned to a pharmaceutical royalty company in December 2022, collecting royalties from licensed products after divesting commercial operations.

• Main revenue sources are royalties and milestone payments from Mayne Pharma and international partners for IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins.

• All former commercial operations are now classified as discontinued operations in financial statements.

• Continues to evaluate strategic alternatives, including potential mergers, acquisitions, or asset sales.

Financial highlights

• Q2 2025 license revenue was $952K–$1.0M, up $718K–$766K from Q2 2024; six-month revenue was $1.35M, up $798K year-over-year.

• Q2 2025 net income was $545K–$551K ($0.05/share) versus a net loss of $1.05M–$1.09M ($0.09/share) in Q2 2024.

• Six-month 2025 net loss was $102K, a significant improvement from a $1.82M loss in the same period of 2024.

• Cash and equivalents at June 30, 2025 were $6.07M–$6.1M, up from $5.06M at year-end 2024.

• Operating expenses for Q2 2025 were $1.65M, down 45.5% year-over-year, mainly due to prior year impairment charges.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months due to unresolved disputes, capital needs, and market uncertainty.

• May pursue additional equity or debt financing; failure to secure funding could force curtailment or discontinuation of operations.

• Actively exploring a range of strategic alternatives, with no set timetable or assurance of outcome.